Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

2015

Медицинский совет, Vol 0, Iss 2, Pp 66-69 (2015)

The global number of patients with diabetes mellitus (DM) has been growing steadily. Over the past decade, the number has more than doubled and reached 371 million people by 2013. [1] In most cases it is type 2 diabetes. The dangerous consequences of DM include micro- and macrovascular complications: nephropathy, retinopathy, lesions of the major blood vessels in the heart, brain and lower limbs. Late complications of DM are a major cause of disability and mortality of the patients.

article

Russian

Remedium Group LLC, 2015.

сахарный диабет, сахароснижающие препараты, гликемия, инкретин, глюкагоноподобный пептид-1, випидия, diabetes mellitus, hypoglycemic agents, glycemia, incretin, glucagon-like peptide-1, vipidia, Medicine